Стиль цитування APA (7-ме видання)

Morgensztern, D., Ong, T., Dols, M., Aix, S., Postmus, P., Lewanski, C., . . . Govindan, R. (2017). ABOUND.2L+: Nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC). Oxford University Press.

Чикаго стиль цитування (17-те видання)

Morgensztern, D., et al. ABOUND.2L+: Nab-paclitaxel (nab-P) +/- CC-486 or Durvalumab in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Oxford University Press, 2017.

Стиль цитування MLA (9-ме видання)

Morgensztern, D., et al. ABOUND.2L+: Nab-paclitaxel (nab-P) +/- CC-486 or Durvalumab in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Oxford University Press, 2017.